Preventing Ubiquitination Improves CAR T Cell Therapy via 'CAR Merry-Go-Around'

Nicole M Chapman; Stephen Gottschalk; Hongbo Chi

doi:10.1016/j.immuni.2020.07.023

Preventing Ubiquitination Improves CAR T Cell Therapy via 'CAR Merry-Go-Around'

Immunity. 2020 Aug 18;53(2):243-245. doi: 10.1016/j.immuni.2020.07.023.

Authors

Nicole M Chapman¹, Stephen Gottschalk², Hongbo Chi³

Affiliations

¹ Department of Immunology, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
² Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: [email protected].
³ Department of Immunology, St Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: [email protected].

PMID: 32814023
DOI: 10.1016/j.immuni.2020.07.023

Abstract

Chimeric antigen receptor (CAR) T cells are potent drivers of antitumor immunity, but promoting durable CAR T cell responses remains challenging. In this issue of Immunity, Li et al. (2020) show that blockade of CAR ubiquitination induces CAR recycling to the cell surface, leading to increased CAR T cell cytotoxicity and longevity by amplifying 41BB-dependent signaling and mitochondrial metabolism.

Publication types

Comment

MeSH terms

Cell Line, Tumor
Down-Regulation
Immunotherapy, Adoptive
Receptors, Antigen, T-Cell / genetics
Receptors, Antigen, T-Cell / metabolism
Receptors, Chimeric Antigen* / genetics
Receptors, Chimeric Antigen* / metabolism
Ubiquitination
Xenograft Model Antitumor Assays

Substances

Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen